<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="auc-fluda-product-crs-icans-hoerster">
    <meta name="study:title" content="PS2144 - AUC fludarabine and product choice are main predictors of CRS/ICANS after CAR T cell therapy: Generation of an improved model">
    <meta name="study:fileName" content="Abstracts/AUC-FLUD-PRODUCT-CRS-ICANS-HOERSTER.html">
    <meta name="study:cancerTypes" content="B-NHL,LBCL">
    <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="Fludarabine,Tisagenlecleucel,Axicabtagene ciloleucel,Lisocabtagene maraleucel,Brexucabtagene autoleucel,CAR-T cell therapy">

    <title>PS2144: AUC Fludarabine & Product Choice in CAR-T (Hoerster) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css"> </head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PS2144 - AUC Fludarabine & Product Choice as CRS/ICANS Predictors in CAR-T Therapy</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=176)</h4>
                    <p>CAR-T Pts (various products, incl. MM). Aim: Develop multivariable prediction models for CRS/ICANS using AUC Fludarabine, mEASIX & product type.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Methods & Model Predictors</h4>
                    <p>Logistic regression models. Predictors: mEASIX, AUC Fludarabine, Age, Liso-cel, MM diagnosis.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Findings (Predictors for ICANS ≥°II / CRS ≥°II)</h4>
                    <p>↑AUC Fluda: Sig. ↑ICANS (OR 2.3, p=0.003) & ↑CRS (OR 1.72, p=0.008). Liso-cel & MM: Sig. ↓ICANS & ↓CRS. mEASIX less pronounced.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Conclusion & Model Performance</h4>
                    <p>AUC Fluda is a key predictor for CRS/ICANS. Liso-cel & MM assoc. with lower risk. ROC AUC: ICANS 0.86, CRS 0.75.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PS2144 - AUC fludarabine and product choice are main predictors of CRS/ICANS after CAR T cell therapy: Generation of an improved model</h1>
            <p class="abstract-sub-header">Keven Hoerster, Jan Pelster, Marcel Teichert, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PS2144 | Poster Presentation</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) are known side effects of CAR T-cell therapy.</li>
                        <li>Elevated modified Endothelial Activation and Stress Index score (mEASIX) is associated with increased odds of CRS/ICANS.</li>
                        <li>Higher effective dose of fludarabine during lymphodepletion (AUC fludarabine) predicts CAR-T outcomes and is linked to ICANS.</li>
                        <li>The combined effect of mEASIX and AUC fludarabine in a prediction model, especially across various CAR-T products (including liso-cel) and in Multiple Myeloma (MM) patients, has not been fully investigated.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <p class="text-sm mb-1">To establish multivariable prediction models for CRS (≥°II) and ICANS (≥°II) based on mEASIX, AUC fludarabine, and specific CAR-T product, encompassing all currently registered products.</p>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Patient Cohort: Data from 176 CAR-T patients.</li>
                        <li>Initial Predictors Considered: AUC fludarabine, mEASIX, gender, age, weight, liso-cel, brexu-cel, and MM diagnosis.</li>
                        <li>AUC Fludarabine Estimation: Using eGFR (CKD-EPI-2021), patient weight, and total fludarabine dose via Langenhorst et al. (2018) model.</li>
                        <li>mEASIX Calculation: log2(mEASIX) scores as previously described (Pennisi et al., 2021).</li>
                        <li>Data Handling: Continuous variables centered and scaled.</li>
                        <li>Modeling: Python v3.12 (numpy/pandas, sklearn for ROC, statsmodel's logit function). Two multivariable logistic regression models fitted using maximum likelihood estimation for ICANS ≥°II and CRS ≥°II.</li>
                    </ul>
                     <div class="study-design-schema">
                        <h3 class="schema-title">Predictive Model Generation for CRS/ICANS</h3>
                        <div class="schema-enrollment">
                            <strong>Patient Data (N=176)</strong>
                            <span>CAR-T Treated Patients (Various Products & Indications incl. MM)</span>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group justify-around">
                            <div class="schema-phase" style="flex-basis: 100%; background-color: var(--sobi-light-gray-bg); border-color: var(--sobi-dark-blue);">
                                <strong>Data Collection & Processing</strong>
                                <span>Calculate AUC Fludarabine & log2(mEASIX)</span>
                                <span>Collect data on product, age, MM status etc.</span>
                                <span>Center & Scale continuous variables</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-phase-group justify-around">
                             <div class="schema-phase" style="background-color: var(--sobi-light-teal-bg);">
                                <strong>Model 1: ICANS ≥°II</strong>
                                <span>Predictors: mEASIX, AUC Fluda, Age, Liso-cel, MM</span>
                            </div>
                            <div class="schema-phase" style="background-color: var(--sobi-light-orange-bg);">
                                <strong>Model 2: CRS ≥°II</strong>
                                <span>Predictors: mEASIX, AUC Fluda, Liso-cel, MM (Age excluded)</span>
                            </div>
                        </div>
                        <div class="schema-arrow-down">▼</div>
                        <div class="schema-assessment-points">
                           <span>Odds Ratios (OR) for predictors</span>
                           <span>Model Performance (ROC AUC)</span>
                        </div>
                    </div>
                </div>
            </div> <div> <div class="abstract-card">
                    <h2 class="abstract-section-title">Results: Predictive Models for CRS & ICANS</h2>
                    <p class="text-sm mb-2">Two multivariable logistic regression models were developed based on data from 176 CAR-T patients. Gender, patient weight, and brexu-cel were excluded as predictors in the final models.</p>

                    <p class="text-sm font-semibold mt-3 mb-1">ICANS ≥°II Model Predictors:</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li><strong>AUC Fludarabine:</strong> Significantly associated with ICANS (OR: 2.3, 95%CI: 1.32-4.00, p=0.003).</li>
                        <li><strong>Liso-cel:</strong> Reduced odds of ICANS (OR: 0.10, 95%CI: 0.02-0.43, p=0.002).</li>
                        <li><strong>Multiple Myeloma (MM):</strong> Reduced odds of ICANS (OR: 0.02, 95%CI: 0.002-0.18, p&lt;0.001).</li>
                        <li>Age: Trend towards higher odds in elderly (OR: 1.81, 95%CI: 0.97-3.36, p=0.059).</li>
                        <li>mEASIX: Trend towards higher odds with increased mEASIX (OR: 1.46, 95%CI: 0.94-2.27, p=0.089).</li>
                    </ul>

                    <p class="text-sm font-semibold mt-3 mb-1">CRS ≥°II Model Predictors (Age excluded):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li><strong>AUC Fludarabine:</strong> Significantly higher odds of CRS (OR: 1.72, 95%CI: 1.14-2.58, p=0.008).</li>
                        <li><strong>Liso-cel:</strong> Lower risk of CRS (OR: 0.15, 95%CI: 0.06-0.39, p&lt;0.001).</li>
                        <li><strong>Multiple Myeloma (MM):</strong> Lower risk of CRS (OR: 0.25, 95%CI: 0.11-0.59, p=0.001).</li>
                        <li>mEASIX: No significantly higher risk (OR: 1.28, 95%CI: 0.90-1.81, p=0.16).</li>
                    </ul>
                    <p class="text-sm font-semibold mt-3 mb-1">Model Performance:</p>
                     <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>ICANS Model ROC AUC: 0.86</li>
                        <li>CRS Model ROC AUC: 0.75</li>
                    </ul>
                    <div class="abstract-card mt-4">
                        <h3 class="text-md font-semibold mb-2 text-center" style="color: var(--sobi-dark-blue);">Figure 1: Model Results</h3>
                        <img src="Assets/Figure_Hoerster_CRS_ICANS.png" alt="Figure 1: Forest plots for ICANS and CRS models, and ROC curves" class="mx-auto rounded-lg shadow-md" style="max-width: 100%; height: auto;">
                        <p class="text-xs text-center mt-2 italic">Figure 1: Forest plots with ORs of the multivariate logistic regression models for ICANS≥°II (A) and CRS≥°II (B). ROC curves corresponding to the ICANS (C) and the CRS prediction model (D).</p>
                    </div>
                </div>
            </div> </div> <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>Elevated AUC fludarabine was significantly associated with an increased risk of severe CRS and ICANS.</li>
                <li>Treatment with lisocabtagene maraleucel (liso-cel) and a diagnosis of Multiple Myeloma (MM) were associated with a decreased risk of severe CRS/ICANS.</li>
                <li>The previously reported association of mEASIX with CRS/ICANS was less pronounced in these multivariable models.</li>
                <li>ROC curves derived from the model predictions demonstrated good predictive performance for both ICANS (AUC 0.86) and CRS (AUC 0.75).</li>
                <li>The authors plan to confirm these results in an external validation cohort with additional predictors.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>AUC, Area Under the Curve; Axi-cel, Axicabtagene ciloleucel; Brexu-cel, Brexucabtagene autoleucel; CAR-T, Chimeric Antigen Receptor T-cell; CI, Confidence Interval; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; CRS, Cytokine Release Syndrome; eGFR, Estimated Glomerular Filtration Rate; ICANS, Immune Effector Cell-Associated Neurotoxicity Syndrome; Liso-cel, Lisocabtagene maraleucel; mEASIX, Modified Endothelial Activation and Stress Index; MM, Multiple Myeloma; OR, Odds Ratio; Pts, Patients; ROC, Receiver Operating Characteristic; Tisacel, Tisagenlecleucel; °II, Grade 2.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">Hoerster K, Pelster J, Teichert M, et al. AUC fludarabine and product choice are main predictors of CRS/ICANS after CAR T cell therapy: Generation of an improved model. Abstract #PS2144 presented at European Haematology Association (EHA) June 12–15, 2025, Milan, Italy.</p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PS2144 | Abstract Release: 05/14/2025 | Presentation: 06/14/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div> <script defer src="abstract_features.js"></script>
    </body>
</html>
